The global cardiac biomarker testing market size was valued at USD 4.3 billion in 2023, driven by the increasing prevalence of cardiovascular diseases across the globe. The market size is anticipated to grow at a CAGR of 8.8% during the forecast period of 2024-2032 to achieve a value of USD 9.2 billion by 2032.
The cardiac biomarker levels in blood are determined by cardiac biomarker test. When heart gets exposed to stress and experience damage from lack of oxygen, cardiac biomarkers become visible in blood. This could be the result of a heart attack. These levels, however, may be excessive for other causes. The concentrations of biomarkers are frequently used to determine the magnitude of a heart attack and the severity of your heart's damage immediately.
The increasing demand for cardiac biomarker testing globally is contributing to the market growth. The rising investments by the government and private healthcare institutions in the research and development of biomarkers to improve the quality of diagnosis, predictive analysis, and prognosis, is further propelling the global cardiac biomarker testing market share. These institutions are also focusing on novel biomarker tests, facilitating technological development in the cardiac biomarker testing, such as identification of biomarkers with the help of artificial intelligence. This will result in specific recognition of elements for biomarkers, along with fast, cheap readers, and disposable tests, to facilitate rapid testing at home.
WHO initiated a program called "Global action plan for the prevention and control of NCDs 2013-2020", aiming to reduce the number of premature deaths from NCDs by 25% by 2025 through nine voluntary global targets. Such initiatives by global organizations are expected to result in positive outcomes.
WHO stated, “At least 50% of eligible people should receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes by 2025”. Due to all these initiatives and guidelines released by the government, the leading companies in the market are focusing on developing on new and more advanced devices and test kits to increase the convenience and reduce the time of diagnosis and enhanced treatment.
The increased awareness among the healthcare professionals and people in general has increased the use of advanced cardiac marker testing systems that enables early detection and diagnosis of various CVD conditions, including heart attack, myocardial infarction, acute coronary, syndrome, and heart failure, which further aids the cardiac biomarker testing market demand.
Market Breakup by Testing Type
Market Breakup by Technology
Market Breakup by Biomarker Type
Market Breakup by Applications
Market Breakup by End User
Market Breakup by Region
The rising prevalence of cardiovascular disorders are greatly driving the market growth. According to World Health Organization WHO, Cardiovascular diseases (CVDs) accounts for estimated 17.9 million lives each year, major cause of death worldwide, further fuelling the global cardiac biomarker testing market growth. The increasing prevalence of cardiac disorders is justifying for the increasing demand of cardiac biomarker testing in the market contributing to the market growth. The geriatric population globally is also rising which is further propelling the market growth as aged people are more susceptible to heart diseases.
CVDs are a group of heart and blood vessels disorders that include coronary heart disease, cerebrovascular disease, and rheumatic heart disease, among other conditions. Referring to the data released by WHO, heart attacks and strokes accounts for nearly four out of five CVD deaths and one third of these deaths are premature in people under 70 years of age.
According to data released by WHO, People living in low- and middle-income countries often do not have the benefit of primary health care programmes for early detection and treatment of people with risk factors for CVDs.
The adaptation of sedentary lifestyle is also a major factor contributing to the increased number of CVDs globally. Consumption of alcohol, tobacco, lack of active sessions of exercise, and rising incidence of hypertension are also major factors impacting the health of people globally leading to CVDs even at younger age, escalating the market growth.
WHO says Health policies emphasizing on conducive environments in order to make appropriate health choices are essential for motivating people to adopt and sustain healthy behaviours. However, governments have started to roll out public policies and guidelines aiming to reduce the cases of CVDs and motivating people to engage in healthy lifestyles.
The increasing awareness about the importance of early diagnosis of CVDs is also directly aiding the cardiac biomarker testing market share. WHO suggests, identification of CVDs on early basis and ensuring early treatment can significantly prevent premature deaths caused by cardiovascular disorders.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Testing Type||
|Breakup by Technology||
|Breakup by Biomarker Type||
|Breakup by Applications||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cardiac Biomarker Testing Market Overview
3.1 Global Cardiac Biomarker Testing Market Historical Value (2017-2023)
3.2 Global Cardiac Biomarker Testing Market Forecast Value (2024-2032)
4 Global Cardiac Biomarker Testing Market Landscape
4.1 Global Cardiac Biomarker Testing Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cardiac Biomarker Testing Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Cardiac Biomarker Testing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cardiac Biomarker Testing Market Segmentation
6.1 Global Cardiac Biomarker Testing Market by Testing Type
6.1.1 Market Overview
6.1.2 Point of Care Testing (POCT)
6.1.3 Laboratory Testing
6.2 Global Cardiac Biomarker Testing Market by Technology
6.2.1 Market Overview
6.2.3 Clinical Chemistry
6.2.4 Molecular Diagnostics
6.3 Global Cardiac Biomarker Testing Market by Biomarker Type
6.3.1 Market Overview
6.3.2 Creatine Kinase (CK-MB)
6.3.5 Natriuretic Peptides (BNP and NT-proBNP)
6.3.6 Ischemia Modified Albumins
6.3.7 Other Biomarkers
6.4 Global Cardiac Biomarker Testing Market by Applications
6.4.1 Market Overview
6.4.2 Myocardial Infraction
6.4.3 Congestive Heart Failure
6.4.4 Acute Coronary Syndrome
6.4.6 Other Applications
6.5 Global Cardiac Biomarker Testing Market by End User
6.5.1 Market Overview
6.5.2 Hospitals and Clinics
6.5.3 Diagnostic Laboratories
6.5.4 Ambulatory Surgical Centers
6.5.5 Research Institutes
6.6 Global Cardiac Biomarker Testing Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Cardiac Biomarker Testing Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Cardiac Biomarker Testing Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Cardiac Biomarker Testing Market
9.1 Market Share by Country
10 Latin America Cardiac Biomarker Testing Market
10.1 Market Share by Country
11 Middle East and Africa Cardiac Biomarker Testing Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 Abbott Laboratories
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.3 Siemens Healthineers AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.4 Beckman Coulter, Inc. (Danaher Corporation)
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.5 bioMérieux SA
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.6 Ortho Clinical Diagnostics
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.7 Becton, Dickinson and Company (BD)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.8 Thermo Fisher Scientific Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.9 Randox Laboratories Ltd.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.10 Bio-Rad Laboratories, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.11 Singulex Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.13 LSI Medience Corporation
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.14 Trivitron Healthcare
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.15 Qingdao Rich Biotechnology Co., Ltd.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisition
17.17 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisition
17.18 Guangzhou Wondfo Biotech Co., Ltd.
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisition
17.19 Abnova Corporation
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisition
17.20 Merck KGaA
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisition
18 Global Cardiac Biomarker Testing Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 4.3 billion in 2023, driven by the reliability it provides.
The market is anticipated to grow at a CAGR of 8.8% during the forecast period of 2024-2032, likely to reach a market value of USD 9.2 billion by 2032.
The rising prevalence of cardiovascular disorders and rising demand of biomarkers testing are two major factors driving the market growth.
The increasing technological development in cardiac biomarker testing, such as integration of artificial intelligence to detect specific elements, is a major trend influencing the market.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Testing available in the market are Point of Care Testing (POCT) and laboratory testing.
The technologies used are immunoassay, clinical chemistry, molecular diagnostics, among others.
The biomarkers in the market are Creatine Kinase (CK-MB), troponins, myoglobin, Natriuretic Peptides (BNP and NT-proBNP), ischemia modified albumins, among other biomarkers.
They find wide applications in myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, among other applications.
The end users are hospitals and clinics, diagnostic laboratories, ambulatory surgical centers, research institutes, among others.
Key players involved in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Beckman Coulter, Inc. (Danaher Corporation), bioMérieux SA, Ortho Clinical Diagnostics, Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., Randox Laboratories Ltd., Bio-Rad Laboratories, Inc., Singulex Inc., Abbott, LSI Medience Corporation, Trivitron Healthcare, Qingdao Rich Biotechnology Co., Ltd., Werfen, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Guangzhou Wondfo Biotech Co., Ltd., Abnova Corporation, and Merck KGaA.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.